On Thursday, as Biogen’s former hemophilia business makes its Nasdaq debut, the market will decide whether the fledgling spinoff is worth its $5 billion valuation.
Called Bioverativ, the company is setting out with Biogen’s two approved hemophilia drugs, about $325 million in cash, and plans to grow into a biotech mainstay. Those two drugs — Eloctate and Alprolix — brought in more than $800 million last year, and analysts expect them to generate a cumulative $1 billion in 2017.
About the Author Reprints
